KR102010600B1 - 대사 활성 프로필을 모니터링 및 분석하는 방법 및 그의 진단 및 치료학적 용도 - Google Patents

대사 활성 프로필을 모니터링 및 분석하는 방법 및 그의 진단 및 치료학적 용도 Download PDF

Info

Publication number
KR102010600B1
KR102010600B1 KR1020137027588A KR20137027588A KR102010600B1 KR 102010600 B1 KR102010600 B1 KR 102010600B1 KR 1020137027588 A KR1020137027588 A KR 1020137027588A KR 20137027588 A KR20137027588 A KR 20137027588A KR 102010600 B1 KR102010600 B1 KR 102010600B1
Authority
KR
South Korea
Prior art keywords
cells
cell
cancer
disease
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137027588A
Other languages
English (en)
Korean (ko)
Other versions
KR20140024871A (ko
Inventor
루벤 티로시
페르난도 파톨스키
하기트 페레트-소로카
Original Assignee
라모트 앳 텔-아비브 유니버시티 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라모트 앳 텔-아비브 유니버시티 리미티드 filed Critical 라모트 앳 텔-아비브 유니버시티 리미티드
Publication of KR20140024871A publication Critical patent/KR20140024871A/ko
Application granted granted Critical
Publication of KR102010600B1 publication Critical patent/KR102010600B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Ecology (AREA)
KR1020137027588A 2011-04-06 2012-04-04 대사 활성 프로필을 모니터링 및 분석하는 방법 및 그의 진단 및 치료학적 용도 Active KR102010600B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472213P 2011-04-06 2011-04-06
US61/472,213 2011-04-06
PCT/IL2012/050125 WO2012137207A1 (en) 2011-04-06 2012-04-04 Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Publications (2)

Publication Number Publication Date
KR20140024871A KR20140024871A (ko) 2014-03-03
KR102010600B1 true KR102010600B1 (ko) 2019-08-13

Family

ID=46124593

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137027588A Active KR102010600B1 (ko) 2011-04-06 2012-04-04 대사 활성 프로필을 모니터링 및 분석하는 방법 및 그의 진단 및 치료학적 용도

Country Status (11)

Country Link
US (3) US8728758B2 (enExample)
EP (1) EP2694962B1 (enExample)
JP (1) JP5990254B2 (enExample)
KR (1) KR102010600B1 (enExample)
CN (1) CN103518133B (enExample)
AU (1) AU2012240953B2 (enExample)
BR (1) BR112013025782B1 (enExample)
CA (1) CA2832031C (enExample)
DK (1) DK2694962T3 (enExample)
ES (1) ES2627154T3 (enExample)
WO (1) WO2012137207A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137207A1 (en) 2011-04-06 2012-10-11 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
US20160262693A1 (en) * 2013-10-14 2016-09-15 Case Western Reserve University Metabolic analyzer for optimizing health and weight management
US10274456B2 (en) 2013-10-22 2019-04-30 Ramot At Tel-Aviv University Ltd. Method and system for sensing
ITRM20130700A1 (it) * 2013-12-19 2015-06-20 Stichting Katholieke Univ Metodo per il rilevamento di cellule tumorali circolanti
CN105303035A (zh) * 2015-09-29 2016-02-03 上海新窝信息科技有限公司 一种健康监测方法及系统
RU2018124339A (ru) 2015-12-09 2020-01-09 Рамот Ат Тель-Авив Юниверсити Лтд. Способ и система для сенсорного обнаружения посредством модифицированной наноструктуры
RU2019108155A (ru) 2016-08-22 2020-09-21 Рамот Эт Тель-Авив Юниверсити Лтд. Способ и система для подкожного сенсорного определения
US11906463B2 (en) 2016-08-22 2024-02-20 Ramot At Tel-Aviv University Ltd. Methods and systems for detecting bioanalytes
JP7356412B2 (ja) 2017-08-21 2023-10-04 サヴィセル ダイアグノスティック リミテッド 肺癌を検出する方法
CN110491511B (zh) * 2019-07-24 2023-04-07 广州知汇云科技有限公司 一种基于围术期危险预警的多模型互补增强机器学习方法
IT202000016429A1 (it) * 2020-07-07 2022-01-07 Univ Degli Studi Udine Metodo per la valutazione dell’attivita’ metabolica di una cellula non-tumorale
EP4251997A4 (en) * 2020-11-26 2025-07-23 12535441 Canada Ltd SPECTRAL DIAGNOSTIC SYSTEM
US20240358835A1 (en) * 2021-08-17 2024-10-31 Orgenesis Inc. Tumor infiltrating lymphocytes with increased metabolic activity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2457391A1 (en) * 2001-08-06 2003-02-20 Vanderbilt University Device and methods for detecting the response of a plurality of cells to at least one analyte of interest
JP4625946B2 (ja) * 2004-11-02 2011-02-02 国立大学法人 岡山大学 ｐＨ測定装置及びｐＨ測定方法
EP1736780A1 (en) * 2005-06-24 2006-12-27 Eppendorf Array Technologies S.A. Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus
JP2009526519A (ja) * 2006-01-17 2009-07-23 セルーメン、インコーポレイテッド 生物学的システム応答の予測方法
WO2007102146A2 (en) 2006-03-06 2007-09-13 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
WO2011000572A1 (de) * 2009-07-02 2011-01-06 Patenthandel Portfoliofonds I Gmbh & Co. Kg Verfahren und vorrichtung zum nachweis von biologischen langzeiteffekten in zellen
EP2476053A4 (en) * 2009-09-08 2014-03-12 Nodality Inc ANALYSIS OF CELL NETWORKS
WO2012137207A1 (en) 2011-04-06 2012-10-11 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Hynes et al., Analytical Biochemistry, 390, (2009), pp. 21-28.*
Otto et al., Cancer Detection and Prevention, 27, (2003), pp. 291-296.*
Sprague LD et al., Clinical Laboratory, Vol. 52(7-8), 2006, pp. 375-384.
Wu M et al., American Journal of Physiology-Cell Physiology, Vol. 292, No. 1, 2007, pp. C125-C136.

Also Published As

Publication number Publication date
US20140255972A1 (en) 2014-09-11
CN103518133A (zh) 2014-01-15
ES2627154T3 (es) 2017-07-26
BR112013025782B1 (pt) 2022-09-06
BR112013025782A2 (pt) 2016-12-20
JP5990254B2 (ja) 2016-09-07
CN103518133B (zh) 2016-08-17
CA2832031C (en) 2019-09-17
EP2694962B1 (en) 2017-03-01
EP2694962A1 (en) 2014-02-12
CA2832031A1 (en) 2012-10-11
AU2012240953B2 (en) 2017-02-23
US9784731B2 (en) 2017-10-10
DK2694962T3 (en) 2017-06-12
WO2012137207A1 (en) 2012-10-11
JP2014512006A (ja) 2014-05-19
US20130224789A1 (en) 2013-08-29
KR20140024871A (ko) 2014-03-03
US20180038849A1 (en) 2018-02-08
US8728758B2 (en) 2014-05-20
AU2012240953A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
KR102010600B1 (ko) 대사 활성 프로필을 모니터링 및 분석하는 방법 및 그의 진단 및 치료학적 용도
Mueller et al. Landscape of innate immune system transcriptome and acute T cell–mediated rejection of human kidney allografts
Ayaub et al. Single cell RNA-seq and mass cytometry reveals a novel and a targetable population of macrophages in idiopathic pulmonary fibrosis
Trentini et al. Interplay between Matrix Metalloproteinase‐9, Matrix Metalloproteinase‐2, and Interleukins in Multiple Sclerosis Patients
Bonham et al. T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival
Zhang et al. Comprehensive analysis of cell population dynamics and related core genes during vitiligo development
Lee et al. Use of a platform with lens-free shadow imaging technology to monitor natural killer cell activity
Karl et al. Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT
Tenuta et al. Circulating natural killer cells as prognostic value for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: correlation with sarcopenia
Chatterjee et al. Single-cell transcriptome and crosstalk analysis reveals immune alterations and key pathways in the bone marrow of knee OA patients
CN109863401A (zh) 一种用以诊断及预断癌症的方法
Shakiba et al. Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine ligand-receptor pairs that drive disease
Dorjbal et al. Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease
Zhang et al. Impaired megakaryopoiesis due to aberrant macrophage polarization via BTK/Rap1/NF-κB pathway in sepsis-induced thrombocytopenia
Li et al. FPR1 affects acute rejection in kidney transplantation by regulating iron metabolism in neutrophils
US20130183686A1 (en) Method of evaluating immunosuppression
Sameir et al. The increased frequency of type 1 regulatory T (Tr1) cells and the altered expression of aryl hydrocarbon receptor (AHR) and interferon regulatory factor-4 (IRF4) genes in type 1 diabetes: a case-control study
Chang et al. Exploring the evolution of T cell function and diversity across different stages of non-small cell lung cancer
Vorperian et al. Cell types of origin in the cell free transcriptome in human health and disease
US20250316378A1 (en) Liquid biopsy for diagnosis of early osteoarthritis
Arum et al. Predictors of mortality in children with neuroblastoma
EP4057005A1 (en) Biomarker for use in cancer therapy
Xiao et al. Single-cell transcriptomics reveals systemic immune dysregulation in non-segmental vitiligo
Ptacek et al. A Systems Immunology Approach Identifies Cytokine-Induced STAT Signaling Pathways Critical to Rheumatoid Arthritis Disease Activity and Treatment Response
Schafflick et al. Single-cell transcriptomics identifies drivers of local inflammation in multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131018

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170403

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180626

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190418

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180626

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190418

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181211

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170403

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20131112

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190521

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190517

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190418

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20181211

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170403

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20131112

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190807

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190807

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220729

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230807

Start annual number: 5

End annual number: 5